Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 732 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over... August 31, 2022 EMA Recommends Granting a Marketing Authorisation for Elacestrant July 26, 2023 Daughter And Her Terminally Ill Dad Go On Bucket List Adventures... January 24, 2022 FDA Proposes Changes to Mammography Standards to Inform Women About Breast... March 28, 2019 Load more HOT NEWS The team tackling the serious side effects of cancer treatment in... Healthy and Delicious Figs Progression-Free Survival and Overall Survival Significantly Longer with Lenvatinib Plus Pembrolizumab... FDA Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive NSCLC
